These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 11708264)

  • 1. In vitro activity of amprenavir against Pneumocystis carinii.
    Atzori C; Fantoni G; Valerio A; Cargnel A
    Int J Antimicrob Agents; 2001 Sep; 18(3):271-3. PubMed ID: 11708264
    [No Abstract]   [Full Text] [Related]  

  • 2. Models for evaluating compounds for activity against Pneumocystis carinii.
    Bartlett MS
    Eur J Clin Microbiol Infect Dis; 1991 Mar; 10(3):199-201. PubMed ID: 2060530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of terbinafine against Pneumocystis carinii in vitro and its efficacy in the treatment of experimental pneumonia.
    Contini C; Manganaro M; Romani R; Tzantzoglou S; Poggesi I; Vullo V; Delia S; De Simone C
    J Antimicrob Chemother; 1994 Nov; 34(5):727-35. PubMed ID: 7706168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro studies of Pneumocystis carinii.
    Cushion MT
    J Protozool; 1989; 36(1):45-52. PubMed ID: 2651655
    [No Abstract]   [Full Text] [Related]  

  • 5. Pneumocystis carinii: growth variables and estimates in the A549 and WI-38 VA13 human cell lines.
    Cushion MT; Ruffolo JJ; Linke MJ; Walzer PD
    Exp Parasitol; 1985 Aug; 60(1):43-54. PubMed ID: 3894045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment and prevention of Pneumocystis carinii pneumonia and further elucidation of the P. carinii life cycle with 1,3-beta-glucan synthesis inhibitor L-671,329.
    Schmatz DM; Powles M; McFadden DC; Pittarelli LA; Liberator PA; Anderson JW
    J Protozool; 1991; 38(6):151S-153S. PubMed ID: 1818147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium transport inhibitors decrease proliferation of Pneumocystis carinii in short-term culture.
    Shaw MM; Kleyman TR; Bartlett MS; Smith JW
    J Eukaryot Microbiol; 1994; 41(5):110S. PubMed ID: 7804203
    [No Abstract]   [Full Text] [Related]  

  • 8. Studies of the susceptibility of Pneumocystis carinii to clindamycin/primaquine in rats.
    Smith JW
    Eur J Clin Microbiol Infect Dis; 1991 Mar; 10(3):201-3. PubMed ID: 2060531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial susceptibility of Pneumocystis carinii in culture.
    Bartlett MS; Eichholtz R; Smith JW
    Diagn Microbiol Infect Dis; 1985 Sep; 3(5):381-7. PubMed ID: 3875445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Algorithmic analysis of in vitro chemotherapy against Pneumocystis carinii.
    Atzori C; Agostoni F; Angeli E; Cargnel A; Drago L; Gismondo MR
    J Eukaryot Microbiol; 1997; 44(6):30S. PubMed ID: 9508418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppressive effect of deferoxamine on the growth of Pneumocystis carinii in vitro.
    Weinberg GA; Shaw MM
    J Protozool; 1991; 38(6):223S-224S. PubMed ID: 1818180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of pentamidine analogues as new agents for the treatment of Pneumocystis carinii pneumonia.
    Tidwell RR; Jones SK; Geratz JD; Ohemeng KA; Bell CA; Berger BJ; Hall JE
    Ann N Y Acad Sci; 1990; 616():421-41. PubMed ID: 2078033
    [No Abstract]   [Full Text] [Related]  

  • 13. [In vitro study of the anti-pneumocystis carinii effect of arteminsin derivatives].
    Ni X; Chen Y
    Zhonghua Jie He He Hu Xi Za Zhi; 2001 Mar; 24(3):164-7. PubMed ID: 11802960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia.
    Kovacs JA; Gill VJ; Meshnick S; Masur H
    JAMA; 2001 Nov; 286(19):2450-60. PubMed ID: 11712941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prodrugs for amidines: synthesis and anti-Pneumocystis carinii activity of carbamates of 2,5-bis(4-amidinophenyl)furan.
    Rahmathullah SM; Hall JE; Bender BC; McCurdy DR; Tidwell RR; Boykin DW
    J Med Chem; 1999 Sep; 42(19):3994-4000. PubMed ID: 10508447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo models of Pneumocystis carinii.
    Bartlett MS; Queener SF; Shaw MM; Durant PJ; Lee CH; Smith JW
    J Eukaryot Microbiol; 1997; 44(6):51S. PubMed ID: 9508437
    [No Abstract]   [Full Text] [Related]  

  • 17. Characterization of the beta-tubulin gene of Pneumocystis carinii.
    Edlind TD; Bartlett MS; Smith JW
    J Protozool; 1991; 38(6):62S-63S. PubMed ID: 1818208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-vitro activity of rifabutin and albendazole singly and in combination with other clinically used antimicrobial agents against Pneumocystis carinii.
    Cirioni O; Giacometti A; Barchiesi F; Fortuna M; Scalise G
    J Antimicrob Chemother; 1999 Nov; 44(5):653-9. PubMed ID: 10552982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effect of a Pichia anomala killer toxin on the viability of rat-derived Pneumocystis carinii.
    Jackson HC; Séguy N; Killigin EM; Dei-Cas E; Polonelli L; Cailliez JC
    J Eukaryot Microbiol; 1996; 43(5):29S. PubMed ID: 8822833
    [No Abstract]   [Full Text] [Related]  

  • 20. Antimicrotubule benzimidazoles inhibit in vitro growth of Pneumocystis carinii.
    Bartlett MS; Edlind TD; Durkin MM; Shaw MM; Queener SF; Smith JW
    Antimicrob Agents Chemother; 1992 Apr; 36(4):779-82. PubMed ID: 1503439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.